GE HealthCare Technologies Inc. (GEHC)
GE HealthCare Technologies is a medical-device manufacturer focused on machines hospitals use to see inside patients. Born in 2023 from the split of General Electric’s healthcare unit, it serves the diagnostic imaging, ultrasound, and cancer radiation-therapy markets — global businesses where customers are hospitals, imaging centers, and cancer treatment facilities that depend on updating equipment on regular cycles.
The machinery of diagnosis
GE HealthCare’s core business is manufacturing imaging machines — the devices that let doctors see what is happening inside a body. The largest segment is diagnostic imaging, encompassing X-ray, computed tomography (CT), and magnetic resonance imaging (MRI) systems. These are capital-intensive machines that a hospital or diagnostic center buys once every seven to ten years, then uses hundreds of times a day for a decade. The ultrasound business operates similarly: smaller, more portable machines that appear in maternity wards, cardiology suites, and emergency departments worldwide. The third major piece, cancer therapy, centers on radiation systems used in oncology — equipment for administering targeted radiation to tumors.
These are not commodity purchases. A hospital board cannot swap imaging equipment like a fleet vehicle. The machine that was installed in 1995 becomes the trusted tool for radiologists and the constraint on what the radiology department can offer. Replacement happens when the machine ages past reliable maintenance, when the hospital expands capacity, or when a new technology proves sufficiently superior to justify the capital expenditure and the disruption of installation. That cycle creates a recurring, predictable demand pattern.
A legacy business in transition
GE spun off its healthcare unit because the healthcare business and the industrial-powerhouse business had diverged. GE’s industrial side sells jet engines, power-generation turbines, and locomotives — lumpy, long-cycle capital sales to energy and rail operators. Healthcare is steadier, recurring, and runs on entirely different rhythms and margins. The spinoff let GE HealthCare focus on the actual growth drivers of the healthcare market — an aging global population, expansion of diagnostic capacity in emerging markets, and the shift toward precision medicine and AI-assisted diagnostics.
The separation also carries inherited strengths. GE HealthCare inherited deep relationships with hospital systems that have bought GE imaging for decades. It has manufacturing footprints in the United States, Europe, and Asia. It has research and development teams with expertise in image processing, signal detection, and radiation therapy — technical moats that a startup cannot quickly replicate. But it also inherited the cost base and organizational culture of a large diversified manufacturer, which means GE HealthCare must navigate the tension between maintaining efficiency and investing in the innovation that keeps hospitals buying upgrades.
How the business generates money
Revenue comes from hardware sales and a growing stream of service agreements. When a hospital buys a CT scanner or ultrasound machine, that is the headline transaction — a seven-figure sale that appears as revenue in one quarter. Far more strategically important is what comes after: the ongoing service contracts that cover maintenance, repairs, software updates, and spare parts. These recurring contracts carry high margins because the marginal cost of servicing installed equipment is far below the price customers will pay to keep their machines running. A hospital cannot let a imaging machine sit idle; it generates revenue every day it operates. The service contract is, from the customer’s perspective, a non-negotiable cost, and from GE HealthCare’s perspective, a predictor of durable, high-margin cash flow.
That shift toward software, services, and recurring models has become central to the company’s growth narrative. As hardware becomes commoditized and competition intensifies from other major players, the stickiness of the service relationship and the data that accumulated over thousands of scans become the real assets. GE HealthCare has been investing in cloud-based tools, AI algorithms trained on imaging data, and analytics platforms that help radiologists and clinicians work faster and more accurately. Selling a diagnostic imaging machine is step one; selling the software and the service ecosystem that makes it more valuable is the business GE HealthCare is building toward.
The competitive landscape
GE HealthCare is not alone. Siemens Healthineers, part of the German conglomerate Siemens, is the largest competitor and operates a similar playbook: hardware, service contracts, and an increasing focus on digital tools. Philips Healthcare, spun from the Dutch electronics group, competes in imaging and ultrasound. Canon Medical Systems competes in CT and ultrasound. Japan’s Hitachi also operates in medical imaging. The market has room for several large players because the geographic scale is vast and the switching costs are high — a hospital that has bought Siemens scanners and trained staff on Siemens tools is not easily converted to a competitor.
That competitive intensity, combined with pricing pressure from hospital systems and healthcare purchasing groups negotiating for volume discounts, means GE HealthCare must manage margins carefully. The installed base of hospitals using the company’s equipment is a competitive advantage, but it is not an impenetrable moat. Innovation, service reliability, and the ability to integrate new capabilities into existing systems are the ongoing battlegrounds.
Geography and growth
GE HealthCare operates globally, but the business has distinct regional dynamics. In developed markets — the United States, Western Europe, Japan, Australia — demand is steady and driven by replacement cycles and capacity expansion within existing healthcare systems. The more interesting growth opportunity is in emerging markets, where healthcare spending is rising as incomes grow and populations age. China, India, Brazil, and Southeast Asia represent long-runway markets where diagnostic capacity remains below developed-world levels and regulatory frameworks are gradually opening to foreign manufacturers.
The company faces tariffs, local-content requirements, and fierce domestic competition in large emerging markets, especially China. It also navigates regulatory variation across countries — approval processes for new imaging machines differ between the FDA in the United States, the European Medicines Agency, and national regulators elsewhere. Managing that global regulatory complexity is a source of both cost and competitive advantage for a large, established manufacturer.
Challenges and the path forward
GE HealthCare must contend with multiple pressures. Healthcare budgets worldwide are under strain, and hospital systems are increasingly price-sensitive and demanding of evidence that new equipment improves patient outcomes or operational efficiency. Rising interest rates make capital purchases more expensive for hospitals. Supply-chain disruptions and inflationary pressure on component costs hit the manufacturer. And the transition from hardware-centric to software-and-services-centric business models requires investment in talent and platforms that do not produce revenue immediately.
The regulatory environment around medical devices is also tightening. Cybersecurity standards are rising, especially as imaging machines become network-connected. Data-privacy rules, particularly in Europe and around healthcare records, constrain how the company can collect and use the vast quantity of imaging data that could power more accurate algorithms.
How to research GE HealthCare
Start with the company’s annual 10-K (SEC CIK 0001932393), which details revenue by geography and business segment, describes the competitive landscape, and lays out risks. Quarterly earnings calls reveal momentum in recurring revenue, margin trends, and management’s commentary on hospital capital spending and the adoption of digital tools. Watch the health of China, which is both a growth market and an area of geopolitical sensitivity.
Key metrics to track are the ratio of service revenue to hardware revenue — as this tilts toward services, the business becomes more durable — and the growth rate of software and cloud solutions. Gross margin trends matter because they signal pricing power or pricing pressure. And order backlogs for imaging equipment give forward-looking insight into hospital capital-spending intentions.